Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Viatris Readies Landmark Botox Biosimilar, Clinical Trial Coming In H1 2024

Key IND Filing With USFDA Planned For Year-End; Launch In 2026 Slated

Executive Summary

Viatris has provided the latest on plans to bring a biosimilar to the world-renowned Botox cosmetic and therapeutic brand, while also discussing other opportunities on the slate, including its pipeline of complex injectables.

You may also be interested in...

Cipla Readies gSymbicort, Semaglutide Amid Sale Speculation ‘Distraction’

Cipla’s US business scales new peak in Q2 amid strong showing overall even as the promoter group stake sale speculation is becoming a 'distraction'. The company has new peptide assets, among others, in the wings while management also points to traction in the 'mRNA journey'.

Malik To Step Down As Viatris President Amid Continuing Strategic Shift

Rajiv Malik is to retire as president of Viatris from 1 April 2024, amid a continuing strategic transformation for the business that was formed by the merger of Mylan and Pfizer’s Upjohn.

Viatris Welcomes FDA Date On Slow-Release Copaxone Product

Viatris and Mapi have moved a step closer to realizing the US launch of their 505(b)(2) once- monthly glatiramer acetate product, a follow-on to Teva’s Copaxone treatment for multiple sclerosis.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts